MDxHealth

Update in progress

MDXH (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

MDxHealth SA is a commercial-stage precision diagnostics company offering urologic tests across the U.S., Europe, and beyond. Its tests include Select mdx (a non-invasive urine test for prostate cancer), Confirm mdx (tissue test validating epigenetic markers on previously negative biopsies), Resolve mdx (UTI-directed antibiotic options), and Genomic Prostate Score (GPS) for personalized cancer insights. It markets via a focused urology sales team and collaborates with the University of Oxford on GPS in the ProtecT trial. Formerly OncoMethylome Sciences, founded 2003, based in Herstal, Belgium.

Company score

Sentiment: -0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive